Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2020115095 - PROCÉDÉS ET COMPOSITIONS POUR LA PRÉVENTION ET/OU LE TRAITEMENT DE L'ISCHÉMIE ET DE LA LÉSION D'ISCHÉMIE-REPERFUSION

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

CLAIMS

1. Glycosylated Apolipoprotein J (Apo J-Glyc) for use in the prevention of ischemia injury.

2. Glycosylated Apolipoprotein J (Apo J-Glyc) or non-glycosylated Apolipoprotein J (non-Glyc Apo J) for use in the treatment of ischemia injury.

3. Glycosylated Apolipoprotein J (Apo J-Glyc) or non-glycosylated Apolipoprotein J (non-Glyc Apo J) for use in the treatment of ischemia-reperfusion injury, wherein the Apo J-Glyc or the non-Glyc Apo J is administered after the onset of the ischemia and before the reperfusion.

4. The glycosylated Apo J for use according to claims 1, 2 or 3 wherein the glycosylated Apo J is glycosylated Apo J containing N-acetylglucosamine (GlcNAc) residues or glycosylated Apo J containing N-acetylglucosamine (GlcNAc) and sialic acid residues.

5. The glycosylated Apo J for use according to any of claims 1 to 4 wherein the glycosylated Apo J has been obtained by purification from human plasma.

6. The glycosylated Apolipoprotein J (Apo J-Glyc) or non-glycosylated Apolipoprotein J (non-Glyc Apo J) for use according to any of claims 1 to 4, wherein the ischemia or ischemia/reperfusion injury is due to a condition selected from the group consisting of infarction, atherosclerosis, thrombosis, thromboembolism, lipid-embolism, bleeding, stent, surgery, angioplasty, end of bypass during surgery, organ transplantation, total ischemia, and combinations thereof.

7. The glycosylated Apolipoprotein J (Apo J-Glyc) or non-glycosylated

Apolipoprotein J (non-Glyc Apo J) for use according to any of claims 1 to 6 wherein the ischemia or ischemia/reperfusion injury is produced in an organ or a tissue selected from the group consisting of heart, liver, kidney, brain, intestine, pancreas, lung, skeletal muscle and combinations thereof.

8. The glycosylated Apo lipoprotein J (Apo J-Glyc) or non-glycosylated Apo lipoprotein J (non-Glyc Apo J) for use according to any of claims 1 to 7, wherein the ischemic injury or ischemia/reperfusion injury is selected from the group comprising organ dysfunction, infarct, inflammation, oxidative damage, mitochondrial membrane potential damage, apoptosis, reperfusion-related arrhythmia, cardiac stunning, cardiac lipotoxicity, ischemia-derived scar formation, and combinations thereof

9. The glycosylated or non-glycosylated Apo J for use according to any of claims 1 to 8 wherein the ischemic or the ischemia/reperfusion injury is due to cerebral ischemia or cardiac ischemia.

10. The glycosylated or non-glycosylated Apo J for use according to claim 9 wherein the cardiac ischemia is caused by acute myocardial infarction (AMI).

11. The glycosylated or non-glycosylated Apo J for use according to any of claims 1 to 10 wherein the glycosylated or non-glycosylated Apo J is administered intravenously.

12. The glycosylated or non-glycosylated Apo J for use according to any of claims 1 to 11 wherein the glycosylated or non-glycosylated Apo J is administered as a single dose.